Testing rituximab safety in boys with DMD
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study tests a medicine called Rituxan (a type of antibody treatment) to see if it is safe and tolerable for boys with Duchenne muscular dystrophy (DMD). It may help reduce muscle damage, but it requires a muscle biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Boys aged 6 to 10 years old (including 10).
- Genetically confirmed Duchenne muscular dystrophy (DMD).
- Have muscle weakness or trouble with motor skills, but can still walk independently and do a 10-meter walk test.
- Able to lie on their back and sit up on their own in less than 30 seconds.
- Must not have used oral corticosteroids (like prednisone) for at least 6 months.
- Willing to have more than one muscle biopsy (a small sample of muscle tissue taken for testing).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
This early-phase study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy (DMD). The goal is to see if it is safe and helps improve muscle function in young boys.
This trial tests a new gene therapy called SPOT-03 to see if it can help the body make dystrophin, a protein that is missing in Duchenne muscular dystrophy (DMD). It is for boys ages 2 to under 8 who can still walk at least 10 meters.
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
This study uses remote technology, like apps or wearable devices, to monitor motor skills and development in boys with Duchenne muscular dystrophy (DMD). It aims to find better ways to measure how the disease progresses over time without requiring frequent clinic visits.
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.